http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105147705-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_99d0d9c448085c74fd3b2d76b56c379d |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C69-157 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-616 |
| filingDate | 2015-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_314e85a6697e29503cfe054ebe895f66 |
| publicationDate | 2015-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105147705-A |
| titleOfInvention | Dry suspension of antipyretic-analgesic anti-inflammatory agent aspirin composition |
| abstract | The invention discloses a dry suspension of an antipyretic-analgesic anti-inflammatory agent aspirin composition, and belongs to the technical field of medicine. The composition is prepared from aspirin, cane sugar, polyving akohol, xanthan gum and aspartame. Aspirin is a new-crystal-form compound, an X-ray powder diffraction map obtained through measurement of Cu-K alpha rays is shown in figure 1, and aspirin is different from aspirin reported in the prior art; it is found through tests that the dry suspension prepared from aspirin the new-crystal-form compound is high in stability and bioavailability and low in free salicylic acid content; when the storage time is prolonged, the free salicylic acid content of the dry suspension is not remarkably increased, and the side effect of medicine on gastrointestinal tract is greatly reduced. |
| priorityDate | 2015-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.